Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2015 2
2016 1
2017 2
2018 6
2019 7
2020 5
2021 9
2022 10
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G, Antonini G, Garibaldi M. Merlonghi G, et al. Autoimmun Rev. 2022 Feb;21(2):102993. doi: 10.1016/j.autrev.2021.102993. Epub 2021 Nov 16. Autoimmun Rev. 2022. PMID: 34798316 Review.
Low fibre size variability with overexpression of both MHC-I and II, associated with C5b-9 deposition, could could be observed in CIM, while increased connective tissue should lead to consider MD, or TM in absence of C5b-9 deposition. ...
Low fibre size variability with overexpression of both MHC-I and II, associated with C5b-9 deposition, could could be observed in CIM …
Statins Neuromuscular Adverse Effects.
Attardo S, Musumeci O, Velardo D, Toscano A. Attardo S, et al. Int J Mol Sci. 2022 Jul 28;23(15):8364. doi: 10.3390/ijms23158364. Int J Mol Sci. 2022. PMID: 35955495 Free PMC article. Review.
Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. ...On this purpose, it is expected that pharmacogenomic and environmental studies will help to timely predict …
Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more …
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ. Connolly CM, et al. Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18. Expert Rev Clin Immunol. 2023. PMID: 37158055 Review.
However, advances utilizing myositis-specific autoantibodies have facilitated the definition of subgroups as well as the prediction of clinical phenotypes, disease course, and response to treatment. AREAS COVERED: Herein we provide an overview of the clinical presentations …
However, advances utilizing myositis-specific autoantibodies have facilitated the definition of subgroups as well as the prediction o …
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O. Mariampillai K, et al. JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598. JAMA Neurol. 2018. PMID: 30208379 Free PMC article.
Cluster 2 (n = 91) regrouped patients who were women and had high creatine phosphokinase levels, necrosis without inflammation, and anti-SRP or anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies corresponding to immune-mediated necrotizing …
Cluster 2 (n = 91) regrouped patients who were women and had high creatine phosphokinase levels, necrosis without inflammation, and anti-SRP …
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis.
Kurashige T. Kurashige T. Curr Opin Rheumatol. 2021 Nov 1;33(6):554-562. doi: 10.1097/BOR.0000000000000832. Curr Opin Rheumatol. 2021. PMID: 34456255 Review.
PURPOSE OF REVIEW: This review aims to describe clinical and pathological features, prognosis and treatment in patients with anti-HMGCR antibody positive immune-mediated necrotizing myopathy (HMGCR-IMNM) based on recent findings. ...Other atypical HMGC …
PURPOSE OF REVIEW: This review aims to describe clinical and pathological features, prognosis and treatment in patients with anti-HMGCR anti …
Peculiar clinicopathological features of immune-mediated necrotizing myopathies.
Allenbach Y, Benveniste O. Allenbach Y, et al. Curr Opin Rheumatol. 2018 Nov;30(6):655-663. doi: 10.1097/BOR.0000000000000547. Curr Opin Rheumatol. 2018. PMID: 30239349 Review.
They have been associated with two myositis-specific antibodies: either anti-signal recognition particle (anti-SRP) or anti-hydroxy-3-methylglutaryl-CoA reductase (anti-HMGCR) antibodies. These two antibodies are now considered as immune-mediated necrotizing …
They have been associated with two myositis-specific antibodies: either anti-signal recognition particle (anti-SRP) or anti-hydroxy-3-methyl …
Immune-mediated necrotising myopathy: A critical review of current concepts.
Day JA, Limaye V. Day JA, et al. Semin Arthritis Rheum. 2019 Dec;49(3):420-429. doi: 10.1016/j.semarthrit.2019.04.002. Epub 2019 Apr 25. Semin Arthritis Rheum. 2019. PMID: 31109639 Review.
Significant advances in the field include the discovery of specific autoantibodies, increased understanding of the risk factors, clinical characteristics and treatment options owing to a wealth of observational studies, and the development of novel classification criteria. …
Significant advances in the field include the discovery of specific autoantibodies, increased understanding of the risk factors, clinical ch …
Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation.
Shelly S, Beecher G, Milone M, Liewluck T, Ernste F, Triplett J, Naddaf E, Zekeridou A, McKeon A, Pittock SJ, Dubey D, Mills JR, Mandrekar J, Klein CJ. Shelly S, et al. Rheumatology (Oxford). 2022 Dec 23;62(1):281-289. doi: 10.1093/rheumatology/keac144. Rheumatology (Oxford). 2022. PMID: 35285492
OBJECTIVES: To investigate immune-mediated necrotizing myopathy (IMNM) association with cancer and its clinical implications. ...Seropositives had greater life expectancy than seronegatives (P = 0.01). CONCLUSIONS: Greater cancer risk is not observe …
OBJECTIVES: To investigate immune-mediated necrotizing myopathy (IMNM) association with cancer and its clinical …
Outcome predictors of immune-mediated necrotizing myopathy-a retrospective, multicentre study.
Wang JX, Wilkinson M, Oldmeadow C, Limaye V, Major G. Wang JX, et al. Rheumatology (Oxford). 2022 Aug 30;61(9):3824-3829. doi: 10.1093/rheumatology/keac014. Rheumatology (Oxford). 2022. PMID: 35022671 Free PMC article.
OBJECTIVES: Evidence-based treatment protocols are currently lacking for immune-mediated necrotizing myopathy (IMNM). In this multicentre retrospective study, we examined baseline clinical characteristics and treatment variables that may predict …
OBJECTIVES: Evidence-based treatment protocols are currently lacking for immune-mediated necrotizing myopathy (I …
Autoimmune Myopathies: Updates on Evaluation and Treatment.
McGrath ER, Doughty CT, Amato AA. McGrath ER, et al. Neurotherapeutics. 2018 Oct;15(4):976-994. doi: 10.1007/s13311-018-00676-2. Neurotherapeutics. 2018. PMID: 30341597 Free PMC article. Review.
The major forms of autoimmune myopathies include dermatomyositis (DM), polymyositis (PM), myositis associated with antisynthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM). ...Newer classifications a …
The major forms of autoimmune myopathies include dermatomyositis (DM), polymyositis (PM), myositis associated with antisynthetase syndrome ( …
56 results